171
Participants
Start Date
August 18, 2020
Primary Completion Date
February 6, 2024
Study Completion Date
April 25, 2024
ID/LAB
ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).
TAU
TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
Penn State Health Milton S. Hershey Medical Center, Hershey
Prisma Health, Greenville
Yale New Haven Hospital, New Haven
National Center for Advancing Translational Sciences (NCATS)
NIH
Yale University
OTHER